cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1102Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯКЛИНИЧЕКАЯ ФАРМАКОЛОГИЯВлияние триметазидина на внутриклеточную концентрацию ионов Са2+ в промиелоцитах линии HL-60 человекаTrimetazidine effects on intracellular Са2+ ion concentration in HL-60 human promyelocytesАсташкинЕ. И.AstashkinE. I.astei@rinet.ruГлезерМ. Г.GlezerM. G.astei@rinet.ruГрачевС. В.GrachevS. V.astei@rinet.ruМосковская медицинская академия им. И.М.Сеченова. МоскваI.M. Sechenov Moscow Medical Academy. Moscow200820102008756267Copyright © Асташкин Е.И., Глезер М.Г., Грачев С.В., 20082008Асташкин Е.И., Глезер М.Г., Грачев С.В.Astashkin E.I., Glezer M.G., Grachev S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1102триметазидинHL-60 клеткиSOC каналырегуляция внутриклеточной концентрации свободных ионов Ca2+TrimetazidineHL-60 cellsSOC channelsregulation of intracellular free Са2+ ion concentrationReferencesYoung LH, Ikeda Y, Scalia R, Lefer AM. Wortmannin, a potent antineutrophil agent, exerts cardioprotective effects in myocardial ischemia/reperfusion. J Pharmac Experim Ther 2000; 295: 37–43.Young LH, Ikeda Y, Scalia R, Lefer AM. Wortmannin, a potent antineutrophil agent, exerts cardioprotective effects in myocardial ischemia/reperfusion. J Pharmac Experim Ther 2000; 295: 37–43.Ikeda Y, Young LH, Lefer AM. Attenuation of neutrophilmediated myocardial ischemia-reperfusion injury by a calpain inhibitor. Am J Physiol Heart Circ Physiol 2002; 282: H1421–6.Ikeda Y, Young LH, Lefer AM. Attenuation of neutrophilmediated myocardial ischemia-reperfusion injury by a calpain inhibitor. Am J Physiol Heart Circ Physiol 2002; 282: H1421–6.Mehta J, Dinerman J, Mehta P, et al. Neutrophil function in ischemic heart disease. Circulation 1989; 79: 549–56.Mehta J, Dinerman J, Mehta P, et al. Neutrophil function in ischemic heart disease. Circulation 1989; 79: 549–56.Hansen PR. Role neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872–85.Hansen PR. Role neutrophils in myocardial ischemia and reperfusion. Circulation 1995; 91: 1872–85.Lefer DJ, Granger DN. Oxidative stress and cardic disease. Am J Med 2000; 109: 315–23.Lefer DJ, Granger DN. Oxidative stress and cardic disease. Am J Med 2000; 109: 315–23.Buja LM, Entman ML. Modes of miocardial cell injury and cell death in ischemic heart disease. Circulation 1998; 98: 1355–7.Buja LM, Entman ML. Modes of miocardial cell injury and cell death in ischemic heart disease. Circulation 1998; 98: 1355–7.Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Ann Rev Physiol 1990; 52: 561–76.Lucchesi BR. Modulation of leukocyte-mediated myocardial reperfusion injury. Ann Rev Physiol 1990; 52: 561–76.Lee C, Xu DZ, Feketeova E, et al. Store-operated calcium channel inhibition attenuates neutrophil function and postshock acute lung injury. J Trauma 2005; 59(1): 56–63.Lee C, Xu DZ, Feketeova E, et al. Store-operated calcium channel inhibition attenuates neutrophil function and postshock acute lung injury. J Trauma 2005; 59(1): 56–63.Chen LW, Shen AY, Chen JS, Wu SN. Differential regulation of Ca2+ influx by fMLP and PAF in human neutrophils: Possible involvement of store-operated Ca2+ channel. Shock 2000; 13(3): 175–82.Chen LW, Shen AY, Chen JS, Wu SN. Differential regulation of Ca2+ influx by fMLP and PAF in human neutrophils: Possible involvement of store-operated Ca2+ channel. Shock 2000; 13(3): 175–82.Hauser CJ, Fekete Z, Goodman ER, et al. CXCR2 stimulation primes CXCR1 [Ca2+] i responses to IL-8 in human neutrophils. Shock 1999; 12(6): 428–37.Hauser CJ, Fekete Z, Goodman ER, et al. CXCR2 stimulation primes CXCR1 [Ca2+] i responses to IL-8 in human neutrophils. Shock 1999; 12(6): 428–37.Putney JW. The pharmacology of capacitative calcium entry. Mol Interv 2001; 1(2): 84–94.Putney JW. The pharmacology of capacitative calcium entry. Mol Interv 2001; 1(2): 84–94.Stanley WC, Marzilli M. Metabolic therapy in the tritment of ischemic heart disease; the pharmacology of trimetazidine. Fund Clin Pharmacol 2003; 17: 133–45.Stanley WC, Marzilli M. Metabolic therapy in the tritment of ischemic heart disease; the pharmacology of trimetazidine. Fund Clin Pharmacol 2003; 17: 133–45.Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: 33e-7.Lopaschuk GD, Barr R, Thomas PD, Dyck JRB. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: 33e-7.Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory effect of trimetazidine on trombin-induced aggregation and calcium entry into human platelets. J Cardiovascular Pharmacology 1994; 23(3): 401–7.Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory effect of trimetazidine on trombin-induced aggregation and calcium entry into human platelets. J Cardiovascular Pharmacology 1994; 23(3): 401–7.Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmac 1993; 22: 828–33.Williams FM, Tanda K, Kus M, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmac 1993; 22: 828–33.Асташкин Е.И., Смирнов О.Н., Гривенников И.А. и др. Верапамил подавляет активность потенциал-управляемых Са2+ каналов и не влияет на активность Са2+ каналов, регулируемых внутриклеточными Са2+ депо, в РС-12 клетках. ДАН 1998; 362(6): 834–7.Асташкин Е.И., Смирнов О.Н., Гривенников И.А. и др. Верапамил подавляет активность потенциал-управляемых Са2+ каналов и не влияет на активность Са2+ каналов, регулируемых внутриклеточными Са2+ депо, в РС-12 клетках. ДАН 1998; 362(6): 834–7.Lytton J, Weslian M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biolog Chemystry 1991; 266(26): 17067–71.Lytton J, Weslian M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biolog Chemystry 1991; 266(26): 17067–71.Tritto I, Wang P, Kuppusamy P, et al. The Anti-Anginal Drug Trimetazidine Reduces Neutrophil-Mediated Cardiac Reperfusion Injury. J Cardiovasc Pharmac 2005; 46(1): 89–98.Tritto I, Wang P, Kuppusamy P, et al. The Anti-Anginal Drug Trimetazidine Reduces Neutrophil-Mediated Cardiac Reperfusion Injury. J Cardiovasc Pharmac 2005; 46(1): 89–98.Di Napoli P. The metabolic approach to improving prognosis in ischemic heart disease. Heart and Metabol 2007; 36: 27–31.Di Napoli P. The metabolic approach to improving prognosis in ischemic heart disease. Heart and Metabol 2007; 36: 27–31.Hunton DL, Lucches PA, Pang Yi, et al. Capacitative calcium entry contributes to Nuclear Factor of Activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J Biol Chem 2002; 277(10): 14266–72.Hunton DL, Lucches PA, Pang Yi, et al. Capacitative calcium entry contributes to Nuclear Factor of Activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J Biol Chem 2002; 277(10): 14266–72.Tabbi-Anneni l, Lucien A, Grynberg A. Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequence in α-adrenergic signaling. Fundam Clin Pharmacol 2003; 17: 51–9.Tabbi-Anneni l, Lucien A, Grynberg A. Trimetazidine effect on phospholipid synthesis in ventricular myocytes: consequence in α-adrenergic signaling. Fundam Clin Pharmacol 2003; 17: 51–9.
The authors declare that there are no conflicts of interest present.